Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.5K

Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes

Amy C Wotherspoon1, Ian S Young1, David R McCance2

  • 1Centre for Public Health, Queen's University Belfast, Belfast, U.K.

Diabetes Care
|September 16, 2016
PubMed

Insights

Fatty acid binding protein 4 (FABP4) levels were higher in pregnant women with type 1 diabetes who developed pre-eclampsia. Elevated FABP4 in the second trimester independently predicted pre-eclampsia risk.

Area of Science:

  • Endocrinology
  • Obstetrics
  • Metabolic Disorders

Background:

  • Pre-eclampsia is a serious pregnancy complication.
  • Type 1 diabetes increases pre-eclampsia risk.
  • Novel biomarkers are needed for early detection.

Purpose of the Study:

  • To investigate the association between fatty acid binding protein 4 (FABP4) and pre-eclampsia risk.
  • To evaluate FABP4 as a potential biomarker in women with type 1 diabetes.

Main Methods:

  • Serum FABP4 levels measured in 710 women with type 1 diabetes during early and second trimesters.
  • Comparison of FABP4 levels between women who developed pre-eclampsia and those who did not.
  • Statistical analysis to determine independent prediction of pre-eclampsia.

Main Results:

  • FABP4 levels were significantly elevated in early and second trimesters in women who developed pre-eclampsia.
  • Elevated second-trimester FABP4 was independently associated with pre-eclampsia (OR 2.87).
  • FABP4 improved risk prediction models for pre-eclampsia.

Conclusions:

  • Increased second-trimester FABP4 independently predicts pre-eclampsia in women with type 1 diabetes.
  • FABP4 demonstrates potential as a novel biomarker for pre-eclampsia prediction.
  • Early identification of pre-eclampsia risk can guide management.
Abstract

More Related Videos

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

3.2K
Electrochemiluminescence Assays for Human Islet Autoantibodies09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

16.2K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
294